ArticleDiscover nano2026
Low-frequency ultrasound-assisted application of Ag/Cu nanocomposites as a promising strategy for the treatment of purulent wounds.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The purpose of this experimental study was to systematically evaluate the synergistic effects of combining low-frequency ultrasound (LF US) with silver/copper nanocomposites (Ag/Cu NCs) for treating experimental purulent wounds infected with multidrug-resistant (MDR) bacteria. The Ag/Cu NCs (size of 73.2 ± 16.7 nm) were synthesized using a combined ultrasound-assisted polyol method. In vitro testing showed that LF US treatment significantly reduced the minimum inhibitory and bactericidal concentrations of Ag/Cu NCs for all tested MDR strains, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. In vivo experiments on rats with purulent wounds revealed that the combination therapy (Ag/Cu NCs + LF US) led to a significantly accelerated healing rate and superior to single-modality treatments of Ag/Cu NCs, LF US or Chlorhexidine. Histological and immunohistochemical analyses provided insights, showing that the combined therapy rapidly resolved inflammation, evidenced by a significantly faster decrease in the pro-inflammatory M1 macrophages and a corresponding earlier and more robust increase in the anti-inflammatory M2 macrophages by day 3. This rapid polarization shift, along with the faster clearance of the bacterial load, promoted the earlier formation of granulation tissue, restoration of normal microcirculation, and epithelialiation. The use of LF US in combination with Ag/Cu NCs promoted local accumulation and systemic absorption of silver and copper with an acceptable safety profile. The combined application of Ag/Cu NCs and LF US presents a promising and highly effective strategy for treating purulent, MDR-infected wounds. These preclinical studies provide strong support for the further optimization and translation of this integrated approach into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.